Sector News

O’Connor resigns as CEO of Advaxis with immediate effect

July 7, 2017
Life sciences

Daniel O’Connor has resigned as CEO of Advaxis. The cancer immunotherapy biotech has put CBO Tony Lombardo in charge while it searches for a permanent successor to O’Connor.

Advaxis provided scant detail about why O’Connor has left the position and board of directors with immediate effect. Both parties provided the usual niceties for a statement disclosing the news. But the sudden, surprising nature of the departure leaves questions unanswered.

O’Connor joined Advaxis as SVP in January 2013. By August, he was CEO. Back then, Advaxis was struggling after data on its cancer vaccine failed to wow. Advaxis suffered further setbacks under O’Connor’s stewardship, including a clinical hold, but overall the situation has improved. O’Connor struck a deal with Amgen, moved an asset into phase 3, steadied Advaxis’ once-perilous financial position and oversaw a 100% increase in its stock.

Responsibility for building on that progress will now fall on Lombardo, at least in the near term. Lombardo, like O’Connor before him, has risen to the CEO post shortly after joining the company. Advaxis originally hired Lombardo as CBO in April.

Lombardo’s résumé includes a stint as CEO of Nasdaq-listed imaging company E-Z-EM that culminated in a $240 million takeover by Bracco Diagnostic. That experience could put Lombardo in the running for the permanent CEO position. But, for now, he is only keeping the seat warm during an important period for Advaxis.

The new leader’s to-do list includes a filing for European approval of axalimogene filolisbac in metastatic cervical cancer. Advaxis plans to submit the application by the end of the year. The asset, which is in phase 3, also has fast-track designation from the FDA.

Shares in Advaxis fell 8% in after-hours trading following the news.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend